CHA
VRCA icon

Carmichael Hill & Associates’s Verrica Pharmaceuticals VRCA Stock Holding History

Carmichael Hill & Associates’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$31 Hold
2
– – ﹤0.01% 774
2024
Q2 		$154 Hold
2
– – ﹤0.01% 764
2024
Q1 		$125 Hold
2
– – ﹤0.01% 755
2023
Q4 		$154 Hold
2
– – ﹤0.01% 779
2023
Q3 		$82 Hold
2
– – ﹤0.01% 780
2023
Q2 		$122 Hold
2
– – ﹤0.01% 776
2023
Q1 		$137 Hold
2
– – ﹤0.01% 768
2022
Q4 		$58 Hold
2
– – ﹤0.01% 775
2022
Q3 		$0 Hold
2
– – ﹤0.01% 874
2022
Q2 		$0 Hold
2
– – ﹤0.01% 874
2022
Q1 		$0 Hold
2
– – ﹤0.01% 840
2021
Q4 		$0 Buy
+2
New +$227 ﹤0.01% 837

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carmichael Hill & Associates's VRCA Position: Q3 2024 in Review

Carmichael Hill & Associates held its Verrica Pharmaceuticals (VRCA) position steady in Q3 2024 at 2 shares worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #774.

Carmichael Hill & Associates first reported a position in VRCA in Q4 2021 and has held it in 12 quarters since. The position peaked at $154 in Q2 2024. 79 funds tracked by Wall St. Rank hold VRCA as of Q3 2024.

  • Carmichael Hill & Associates held 2 shares of Verrica Pharmaceuticals worth $31 as of Q3 2024.
  • Carmichael Hill & Associates left its Verrica Pharmaceuticals share count unchanged in Q3 2024.
  • Verrica Pharmaceuticals made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #774 holding.
  • Carmichael Hill & Associates first reported a position in Verrica Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • Carmichael Hill & Associates's Verrica Pharmaceuticals position peaked at $154 in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.